By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 130.67 |
Change Today | $ 2.92 |
% Change | 2.29 % |
52 Week High | $131.26 |
52 Week Low | $127.00 |
Volume | 1,327,710 |
Shares Issued | 145.80m |
Market Cap | $19,052m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 7 |
Neutral | 21 |
Sell | 1 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 242,199 @ $130.67 |
15:59 | 1,466 @ $130.73 |
15:59 | 100 @ $130.73 |
15:59 | 100 @ $130.74 |
15:59 | 100 @ $130.70 |
You are here: research